Best of ASCO 2019: Breast and Gastrointestinal Cancers – UNC Cancer Network Medical and Surgical Oncology Lecture

Please join the UNC Cancer Network for an online telehealth lecture with Autumn McRee, MD, and Emily Ray, MD, MPH. The American Society of Clinical Oncology (ASCO) hosts an annual conference that features some of the latest oncology research. Join us as our speaker highlights some of the top presentations from this year’s ASCO conference. This lecture focuses on the top research for Breast and Gastrointestinal Cancers at the 2019 ASCO conference.

When Jul 24, 2019
from 12:00 PM to 01:00 PM
Where https://unclineberger.org/unccn/event/best-of-asco-2019-1
Contact Name
Contact Phone 919-445-1000
Attendees Autumn McRee, MD, and Emily Ray, MD, MPH
Add event to calendar vCal
iCal

Best of ASCO 2019: Breast and Gastrointestinal Cancers — Medical and Surgical Oncology Lecture

July 24 @ 12:00 pm - 1:00 pm

Free

UNC Cancer Network's Medical and Surgical Oncology lecture logo with Free CME, CNE, ACPE, and ASRT continuing education credits mark

 

Autumn McRee, MD

Autumn McRee, MD

Associate Professor
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

Emily Ray, MD, MPH

Emily Ray, MD, MPH

Hematology-oncology Fellow
UNC Lineberger Comprehensive Cancer Center
UNC School of Medicine
University of North Carolina at Chapel Hill

 

Best of ASCO 2019: Breast and Gastrointestinal Cancers

 

Lecture Description

The American Society of Clinical Oncology (ASCO) hosts an annual conference that features some of the latest oncology research. Join us as our speaker highlights some of the top presentations from this year’s ASCO conference. This lecture focuses on the top research for Breast and Gastrointestinal Cancers at the 2019 ASCO conference.

Lecture Objectives:
  • Review the role of PARP inhibition in treating metastatic pancreatic cancer with germline BRCA mutations
  • Discuss whether FOLFOXIRI should be considered 1st line standard of care in metastatic colorectal cancer
  • Describe neoadjuvant and adjuvant therapy options for patients with HER2+ breast cancer
  • Identify the principal findings of the MONALEESA-7 trial of endocrine therapy with or without ribociclib

 


More information about this event…